Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.

ABSTRACT:

Purpose

Circulating tumor cells (CTC) represent a new outcome-associated biomarker independent from known prognostic factors in metastatic breast cancer (MBC). The objective here was to develop and validate nomograms that combined baseline CTC counts and the other prognostic factors to assess the outcome of individual patients starting first-line treatment for MBC.

Experimental design

We used a training set of 236 patients with MBCs starting a first-line treatment from the M.D. Anderson Cancer Center (Houston, TX) to establish nomograms that calculated the predicted probability of survival at different time points: 1, 2, and 5 years for overall survival (OS) and 6 months and 1 and 2 years for progression-free survival (PFS).The covariates computed in the model were age, dise

SUBMITTER: Giordano A 

PROVIDER: S-EPMC3662240 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature